Nexara Health — Health Canada Drug Establishment Licence #3-002896

NEUPRO 2 MG / 24 HOUR

Last verified 2026-09-08 · Source: Health Canada Drug Product Database (DPD), DIN 02403900

NEUPRO 2 MG / 24 HOUR

ROTIGOTINE : 2 MG / 24 HOUR · DIN 02403900 · UCB CANADA INC

Health Canada status: MARKETED

What is NEUPRO?

NEUPRO 2 MG / 24 HOUR contains ROTIGOTINE : 2 MG / 24 HOUR. It is listed in the Health Canada Drug Product Database under DIN 02403900, held by UCB CANADA INC, supplied as PATCH for TRANSDERMAL administration. Health Canada currently lists it as marketed, status dated 27-Jun-2013. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.

What is NEUPRO used for?

Treatment of signs and symptoms of idiopathic Parkinson’s disease (early or advanced as adjunct to levodopa) and symptomatic treatment of moderate to severe idiopathic Restless Legs Syndrome (RLS).

Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.

Product details and regulatory record

DIN02403900
Brand nameNEUPRO
Generic / active ingredientROTIGOTINE : 2 MG / 24 HOUR
ManufacturerUCB CANADA INC
Strength2 MG / 24 HOUR
Dosage formPATCH
Route of administrationTRANSDERMAL
SchedulePrescription
ATC codeN04BC09 ROTIGOTINE
AHFS class28:36.20.08
BiosimilarNo
Health Canada statusMARKETED
Status date27-Jun-2013
Original market date2013-06-27 00:00:00

How is it administered?

Transdermal patch applied once daily. Titrate dose gradually to clinical tolerability. Rotate application sites daily; do not reuse same site within 14 days. Taper during discontinuation.

Included because it drives pack selection and wastage. Consult the monograph.

How is it stored and handled?

Not specified in the provided text snippet (refer to full monograph).

How is it supplied?

Not explicitly detailed in provided text beyond strength/size descriptions; typically patches in pouches.

Contraindications

Hypersensitivity to the active substance or to any of the excipients (e.g., sodium metabisulfite).

Warnings and precautions

Sudden onset of sleep; orthostatic hypotension; hallucinations; impulse control disorders (gambling, sexual urges); application site reactions; contains sulfites; skin burns during MRI.

What can be used instead?

Other Canadian products sharing ATC code N04BC09 ROTIGOTINE. 6 of 6 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.

ProductStrengthFormManufacturerHealth Canada statusDIN
NEUPRO1 MG / 24 HOURPATCHUCB CANADA INCMARKETEDDIN 02403897
NEUPRO3 MG / 24 HOURPATCHUCB CANADA INCMARKETEDDIN 02403919
NEUPRO4 MG / 24 HOURPATCHUCB CANADA INCMARKETEDDIN 02403927
NEUPRO6 MG / 24 HOURPATCHUCB CANADA INCMARKETEDDIN 02403935
NEUPRO8 MG / 24 HOURPATCHUCB CANADA INCMARKETEDDIN 02403943

How can I get it?

Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.

Request a quote for NEUPRO

Ordering questions

Who can buy this from Nexara?

Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.

Is there a minimum order?

Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.

What is the lead time?

Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.

Can Nexara supply this for a clinical trial?

Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.

Related pages

Sourcing this product